Sign up USA
Proactive Investors - Run By Investors For Investors

Former Callitas Health CEO Gary Thompson passes away after battle with cancer

James Thompson took over the reins of the Cincinnati-based health and wellness company from his uncle earlier this year
Gary Thompson
Former Callitas Health CEO Gary Thompson was very well regarded in the pharmaceutical industry

Cincinnati-based health and wellness company Callitas Health Inc (CSE:LILY, OTCQB:MPHMF, OTCMKTS: MPHMF) announced Friday that former CEO Gary A Thompson died after a long battle with cancer.

Thompson, who died Tuesday, was a pharmaceutical industry veteran with a career spanning over three decades. He worked with pharmaceutical giants and startups. He served as vice president of sales for Cigna Healthcare (NYSE:CI) before taking over the reins of M Pharmaceutical Inc and later Callitas Health. Thompson was a graduate of Northern Kentucky University, with a BS in Kinesiology.

Callitas Health CEO James Thompson, took over the mantle from his uncle, Gary, earlier this year.

“Gary was a larger-than-life figure who brought his remarkable passion, experience and energy to Callitas Health and he will be greatly missed,” said Callitas Board member William Rodgers.

Callitas Health, which is now spearheaded by the second generation of Thompsons, is a well-diversified company. It has a nimble strategy focused on getting quick revenues from mass-appeal over-the-counter products and a more long-term blockbuster pipeline. It is active across five silos: OTC sexual health & wellness, prescriptions for female sexual health, weight management, cannabis delivery technologies and orphan drugs.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use